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Abstract We have examined the integrity of J774 cell nitric
oxide (NO) production and glutathione maintenance, whilst
NADPH supply was compromised by inhibition of the pentose
pathway with 6-aminonicotinamide. In resting cells 6-phospho-
gluconate accumulation began after 4 h and glutathione depletion
after 24 h of 6-aminonicotinamide treatment. Cellular activation
by lipopolysaccharide/interferon-V decreased glutathione by
V50% and synchronous 6-aminonicotinamide treatment ex-
acerbated this to 31.2% of control (P60.05). In activated cells
NO32 production was inhibited by 60% with 6-aminonicotina-
mide (P60.01), and superoxide production by 50% (P60.01) in
zymosan-activated cells. NADPH production via the pentose
pathway is therefore important to sustain macrophage NO
production whilst maintaining protective levels of glutathione.
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1. Introduction
We have previously employed the anti-metabolite 6-amino-
nicotinamide (6-AN) to investigate the role of the pentose
pathway (PP) in providing NADPH [1]. 6-AN is taken up
by cells and transformed into 6-amino-NADP by NAD-gly-
cohydrolase (EC 3.2.2.5). This NADP analogue inhibits
6-phosphogluconate dehydrogenase (6-PGDH) with a Ki of
0.13U1036 M, approximately 400-fold more powerful than
its inhibition of other NADP(H) requiring enzymes, including
glutathione reductase and glucose 6-phosphate dehydrogenase
(G6-PDH) [2].
Nitric oxide (NO), produced by activated in£ammatory
cells, plays an important role in the immune response, regu-
lating both tumour and parasite growth [3^5]. The synthesis
of NO is dependent on cofactor availability [6,7] with
NADPH providing the reducing equivalents (i) directly for
arginine reduction and (ii) indirectly for the formation of tet-
rahydrobiopterin (BH4). It has been suggested that BH4 is not
a catalytic cofactor, but rather activates NO synthase by sta-
bilising the enzyme in its dimeric form and maintaining key
groups in a reduced state [8]. Both de novo biosynthesis and
salvage of BH4, and dihydrobiopterin reduction require
NADPH. In macrophages the oxidative section of the PP,
via the activity of G6-PDH and 6-PGDH, is a major source
of this cofactor [9], although mitochondrial NADP dehydro-
genases linked to malate and isocitrate also contribute to
NADPH supply [10]. This provision of NADPH is critical
to the maintenance of reducing power within the cell and is
regulated by the redox state of the NADPH/NADP couple.
We have previously demonstrated in J774 cells that this redox
couple is under oxidative pressure when NO is actively being
synthesised [11].
NADPH performs other essential cellular functions, includ-
ing maintenance of glutathione in the reduced form. Gluta-
thione plays a vital role as a cellular antioxidant, protecting
against free radical-mediated cytotoxicity. The intracellular
thiol status is maintained in a reduced state by glutathione,
allowing sulphydryl-dependent enzymes, signal transduction
and gene expression, to function normally [12,13]. There is
evidence that glutathione performs a similar function in main-
taining NO synthase activity [14,15].
NADPH consumption may also occur in the presence of
high glucose concentrations via autoxidation of both free and
protein-associated glucose [16,17], and by activation of the
aldose reductase-mediated polyol pathway [18]. In addition,
aldose reductase can act as a sepiapterin reductase [19]. Thus,
in conditions of high glucose concentration, both substrate
competition between glucose and sepiapterin, and restricted
NADPH availability could limit vital components of the
NO synthase system. Such interactions might contribute to
the disruption of NO homeostasis in diabetes.
In this study we have used a mouse macrophage cell line,
J774.2, to examine the competition for available NADPH
when either the PP is inhibited by 6-AN, or when high glucose
concentrations are present. NADPH-requiring systems exam-
ined were (i) the intracellular redox status (glutathione), (ii)
NO production from inducible NO synthase and (iii) super-
oxide production occurring during phagocytosis.
2. Materials and methods
2.1. Materials
Lipopolysaccharide (LPS) was supplied from Difco Laboratories,
West Molesey, UK. RPMI 1640 medium, Hanks’ balanced salt sol-
ution with calcium, magnesium and bicarbonate, HEPES pH 7.2,
foetal calf serum (FCS), penicillin and streptomycin were purchased
from Life Technologies, Paisley, UK. Glutathione, glutathione reduc-
tase, superoxide dismutase, NADPH, 6-phosphogluconate dehydro-
genase, haemoglobin, tetrahydrobiopterin and 6-aminonicotinamide
were all supplied from Sigma, Poole, UK. All other chemicals used
were Analar or equivalent grade. The aldose reductase inhibitor sor-
binil was a gift from P¢zer UK and murine interferon-V (V-IF) was a
gift from Dr A Sergeant, NIBSC, Potters Bar, UK.
2.2. Macrophage activation
J774.2 cells were grown in RPMI 1640 supplemented with 10%
FCS, penicillin (100 U/ml) and streptomycin (100 Wg/ml) as previously
described [9]. Cells were grown to con£uence in 96-well £at-bottomed
micro-titre plates (200 Wl/well), and activated with LPS plus V-IF
(20 ng/ml and 12 IU/ml respectively), followed 4 h later by treatment
with 6-AN (200 WM). Medium was removed for nitrite determination
20 h after activation, and the remaining adherent cells washed in
phosphate bu¡ered saline, frozen and stored at 370‡C for glutathione
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and 6-phosphogluconate analysis. In some instances medium was re-
moved after 20 h, and the cells washed once in Hanks’ balanced salt
solution with 10 mM HEPES pH 7.2. Culture medium was then
restored and cytokine activation re-initiated, followed by a further
20 h incubation period.
Cells grown under identical conditions, but in 35-mm tissue culture
dishes, were used for superoxide measurements. Prior to activation
with opsonised zymosan, medium was replaced with Hanks’ balanced
salt solution containing 10 mM HEPES pH 7.2 and 5% FCS.
Cells were incubated with 5 mM (control) or 50 and 100 mM
glucose, which was added 15 min after cell activation. Sorbinil (30
WM) was used to inhibit aldose reductase.
2.3. Nitrite measurement
Nitrite (NO32 ) concentration in the medium was determined by the
Griess reaction [20]. Brie£y, 100 Wl of conditioned medium was mixed
with an equal volume of Griess reagent [naphthylethylenediamine
dihydrochloride (0.1% w/v) plus sulphanilamide (1% w/v in H3PO4
5% v/v)] at room temperature. The absorbance at 540 nm was then
determined after 5 min using a Dynatec MR5000 plate reader. NO32
concentration was calculated using sodium nitrite as a standard.
2.4. Glutathione measurement
Total glutathione (GSH+GSSG) was measured in cell lysates using
the Tietze method of recycling reduced glutathione with glutathione
reductase and NADPH [21]. The reduced glutathione was detected by
the colour change at 412 nm associated with 5,5-dithio-bis(2-nitro-
benzoic acid) (DTNB) reduction. This assay was adapted for use in
a microtitre plate using a Dynatec MR5000 plate reader at 405 nm
and Mikrotek kinetics software [11]. Cells were lysed by adding 100 Wl
water containing 1 mM EDTA to each well and freezing immediately.
Following thawing, plates were shaken for 30 s and then sonicated for
60 s at room temperature. Assays were carried out immediately. Val-
idation of this procedure was carried out by processing 20^100 pmol
of GSH and GSSG as above, and by including GSH and GSSG
internal standards in J774 extracts. Recovery was s 95% in all in-
stances.
2.5. Superoxide measurement
Superoxide production by J774 cells was measured by superoxide
dismutase inhibitable lucigenin-enhanced chemiluminescence (CL), as
described previously [5]. Cells were activated with opsonised zymosan
and lucigenin CL measured from time zero for 60 min at 6-min
intervals.
2.6. 6-Phosphogluconate (6-PG) measurement
Frozen cell samples were extracted with 200 Wl of 0.5 N perchloric
acid and centrifuged at 14 000Ug for 2 min. Supernatants were ad-
justed to pH 5^7.5 with 10 Wl of 50% ethanolamine and 3 N potas-
sium hydroxide and centrifuged at 14 000Ug for 2 min. This super-
natant was then assayed for 6-phosphogluconate by measuring
spectrophotometrically at 340 nm, NADP reduction catalysed by
6-PGDH, as previously described [14].
2.7. NO synthase assay
Cells were grown to con£uence in 25-cm2 £asks, and activated for
24 h with LPS/V-IF, then harvested by scraping after treatment with
calcium/magnesium-free Hanks containing 1 mM EDTA. Cells were
collected by centrifugation (400Ug for 5 min), resuspended in 250
mM sucrose containing 20 mM triethanolamine pH 7.4 and sonicated
at 4‡C for 30 s (1600 W and 80 WM). NO synthase was measured in
activated cell sonicates (control and 6-AN treated) and the e¡ect of
the inclusion of non-activated 6-AN treated cell extracts studied. En-
zyme activity was determined from the rate of met-haemoglobin for-
mation (v absorbance at 401 and 419 nm) over 15 min at 37‡C in a
Cary 1E spectrophotometer. Activity was calculated using a g401ÿ419
of 76 mM31 cm31. Each assay (1 ml) contained 50 mM potassium
phosphate pH 7.2, 60 mM valine, 3 WM oxyhaemoglobin, 1.25 mM
magnesium chloride, 0.25 mM calcium chloride, 100 WM arginine, 2
mM glutathione, 100 WM NADPH, 5 WM BH4 and 200 units of SOD.
3. Results
Resting con£uent J774 cells treated with 6-AN began to
accumulate 6-PG after 4 h, and reached a plateau by 24 h
(Fig. 1). This evidence of 6-PGDH inhibition preceded, by
approximately 20 h, a decrease in total glutathione. The rapid
and irreversible decrease in glutathione obtained after treat-
ment with a combination of diamide and BCNU is shown for
comparison. In pre-con£uent cell populations, 6-AN treat-
ment began lowering glutathione within 1 h of the start of
6-PG accumulation (data not shown).
In view of this time course, all further studies were carried
out on fully con£uent cells treated with 6-AN for 16 h. Dur-
ing macrophage activation experiments addition of LPS plus
V-IF was made 4 h before the start of the 6-AN treatment
period. This strategy avoided (1) interference caused by either
a decreased cellular glutathione, or a direct e¡ect of nicotina-
mide on LPS/V-IF NOS induction [9,22], and (2) any possi-
bility that glutathione reductase inhibition might mimic
NADPH competition.
In cells activated with LPS plus V-IF, as previously de-
scribed a decrease in glutathione was observed [11], which
was compounded by 6-AN treatment (Fig. 2a). When these
cells were washed and subjected to a change of medium, glu-
tathione levels increased in all treatments after 20 h. However,
at this time, glutathione decreased in resting cells treated with
6-AN. In the LPS/V-IF treated cells the loss of glutathione
due to cell activation was reversed, but in 6-AN treated acti-
vated cells, some glutathione recovery occurred but failed to
achieve the level to that of the control (Fig. 2b).
NO production (medium nitrite) resulting from cell activa-
tion was also severely inhibited in 6-AN treated cells, and this
inhibition persisted through washing and medium replenish-
ment (Fig. 2a,b). We have used nitrite levels to evaluate NO
production in this study. We have previously shown [5] that
cytokine activated J774.2 cells produce 50% nitrite and 50%
nitrate, however, the ratio of these two products can change
in the presence of elevated superoxide due to peroxynitrite
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Fig. 1. E¡ect of 6-aminonicotinamide on total glutathione and
6-phosphogluconate concentrations in J774 cells. Each value is the
mean þ S.E.M. of six observations. Solid lines are glutathione con-
centrations and dashed line is 6-phosphogluconate concentration.
Table 1
E¡ect of 6-aminonicotinamide on J774 cell NO synthase activity
Treatment Wmol/min/106 cells
A. Non-activated+6-AN N.D.
B. Activated 0.78 þ 0.10 N.S.
C. Activated+6-AN 0.66 þ 0.74 N.S.
A+B 0.83 þ 0.91 N.S.
A+C 0.75 þ 0.52 N.S.
Each value is the mean þ S.E.M. of four experiments. N.D.: not de-
tected; N.S.: not signi¢cant.
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formation. Activation of these cells using LPS/V-IF does not
result in superoxide production, as determined by lucigenin
CL (data not shown), and during activation with zymosan
superoxide production is complete after 1.5 h, well in advance
of any evidence of iNOS activity.
The e¡ect of 6-AN was not a result of direct NO synthase
inhibition, as enzyme maximal activity measured in activated
J774 lysates was not signi¢cantly di¡erent from that measured
in lysates of activated and 6-AN treated cells. Further, activity
was not modi¢ed when 6-AN treated lysates from resting cells
were co incubated (Table 1).
In addition to this e¡ect on the NO synthesising potential
of macrophages, the capacity to produce superoxide following
activation with opsonised zymosan (lucigenin CL) was also
inhibited by over 50%. (P6 0.001) in 6-AN pre-treated cells
(Fig. 3). Lucigenin CL was 98% inhibitable by superoxide
dismutase (44 U/ml: data not shown).
The possibility that high glucose concentration could create
competition for NADPH either by aldose reductase activity or
by glucose autoxidation was examined. Treatment for 24 h
with glucose (50 and 10O mM) failed to cause a signi¢cant
fall in cellular glutathione concentrations (Fig. 4). The de-
crease in glutathione caused by cytokine activation was par-
tially reversed when J774 cells were incubated with 100 mM
glucose, and this reversal was independent of aldose reductase
(sorbinil 30 WM). In activated cells, there was a small but
signi¢cant decrease in nitrite production in the presence of
100 mM glucose (V20%, Ps 0.05) and sorbinil did not re-
verse this fall. This e¡ect on NO production was additive to
that of 6-AN, with a further signi¢cant fall of 20% apparent
in the 100 mM glucose/6-AN treated group.
At normal (5 mM) glucose concentrations, sorbinil did not
a¡ect glutathione levels or nitrite production in resting or
activated cells. Culture of cells in arginine-free medium, or
in the presence of the NO synthase inhibitor LNIO, prevented
the activation-induced decrease in glutathione, and this was
accompanied by a correspondingly lower production of nitrite
(data not shown).
4. Discussion
We have previously shown that during the production of
NO, glutathione concentrations in J774 cells were decreased in
a NO synthase-dependent fashion [11]. We now demonstrate,
using the anti-metabolite 6-AN, that macrophage NADPH
provision via the PP is a key factor in NO production during
cytokine-mediated activation. We also show that inhibition of
this source of NADPH during activation compounds an al-
ready depleted intracellular glutathione, and that this results
from competition for NADPH between glutathione reductase
and NO synthase.
Addition of 6-AN to the culture medium resulted in the
accumulation of 6-PG, indicating that J774 cells are able to
synthesise 6-amino-NADP via glycohydrolase. The cytosolic
NADPH/NADP redox couple in resting cells is maintained
in the reduced form (NADPH to NADP ratio of 100 to 1)
by the activity of NADP reducing enzymes. When NADPH
is consumed during the reductive steps of NO and superoxide
formation, or during disulphide reduction, the redox status is
restored either by the oxidative segment of the PPP or by
mitochondrial malate and isocitrate reductase. In neutrophils
devoid of mitochondria the former is the only means of
NADP reduction, whilst in macrophages both can be de-
ployed. As a result, glutaminolysis, a favoured route of energy
metabolism in macrophages, can provide malate for NADP-
dependent ‘malic’ enzyme and thus shift part of the burden of
NADPH production from glucose to glutamine metabolism.
Nevertheless, our demonstration that 6-AN, a speci¢c PP in-
hibitor, can decrease NO and superoxide production during
activation emphasises the important contribution towards
NADPH provision, made by the PP. Despite a rapid turnover
of glutathione in resting macrophages, 6-AN failed to lower
this thiol in con£uent cells until 24 h had elapsed. However, in
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Fig. 4. E¡ect of medium glucose (50 and 100 mM) on J774 cell glu-
tathione and nitrite production following cytokine activation. Each
value is the mean þ S.E.M. of six observations. Open bars: gluta-
thione; closed bars: nitrite. *P6 0.05 and **P6 0.01 vs non-acti-
vated control, 2P6 0.05 and 22P6 0.01 vs LPS/V-IF activated con-
trol and VP6 0.05 vs LPS/V-IF activated 6-AN treated.
Fig. 2. E¡ect of 6-aminonicotinamide on J774 cell glutathione and
nitrite production, following activation with LPS and IF-V. Each
value is the mean þ S.E.M. of six observations. **P6 0.01 vs con-
trol, 2P6 0.05 vs LPS/V-IF and 22P6 0.01 vs LPS/V-IF.
Fig. 3. E¡ect of 6-aminonicotinamide treatment on zymosan-in-
duced superoxide production in J774 cells. Each value is the
mean þ S.E.M. of six observations.
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activated cells, where competition for NADPH is far more
acute, marked glutathione depletion occurred before 24 h. A
similar decrease in NO production has also been reported in
cerebellar slices using an alternative nicotinamide analogue,
3-acetylpyridine. However, in this instance the change was
attributed to in vivo structural damage to Purkinje cells re-
sulting from dea¡erentation of climbing ¢bres, rather than to
metabolic perturbations in the redox state [23].
Other factors must be considered, the most important being
the synthesis of BH4, which is also inhibited by 6-AN [24].
NO synthase becomes an uncoupled NADPH oxidase when
either BH4 or arginine concentrations fall below a critical
level. Under these conditions, NOS produces less NO, but
more superoxide. Hence, when NADPH demand cannot be
met, BH4 depletion could compound the down-regulation of
NO production resulting from limited availability of
NADPH.
An association has been reported between cell vulnerability
to the cytotoxic e¡ects of NO and glucose availability [25].
Our data support this association, as the decrease in gluta-
thione due to cellular activation observed at physiological
glucose levels was abolished when the glucose concentration
was raised. This could be related to the phenomenon of glu-
cose sparing by glutamine discussed above, and suggests that
at physiological levels glucose becomes a limiting factor in
NADPH production in activated macrophages.
In our experiments a high concentration of glucose failed to
change the level of glutathione in resting cells, but did pro-
duce a small and signi¢cant decrease in NO production during
activation. This decrease caused by high glucose was additive
to that caused by 6-AN, providing evidence that competition
for NADPH was compounded. However, this glucose e¡ect
was not associated with polyol pathway activity, in agreement
with recent studies in J774 and mesangial cells [26,27]. Aldose
reductase was also not involved in the reversal of glutathione
depletion during cytokine activation. These data point to an
action of glucose on NO production through some route other
than NADPH competition, which may be depletion of cellular
arginine [27].
In conclusion, our data demonstrate that NADPH derived
from the PP is essential to maintain normal redox homeostasis
in macrophages actively synthesising NO.
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